avec
la
multipl
de
ca
de
syndrom
respiratoir
aigu
du
au
sra
certain
concern
le
inhibiteur
de
lenzym
de
convers
de
langiotensin
iec
et
le
antagonist
de
de
type
langiotensin
ii
arb
ont
lenzym
membranair
enzym
de
convers
de
langiotensin
sert
de
au
sra
permett
ainsi
son
dan
le
cellul
ainsi
la
craint
quun
traitement
par
iec
ou
arb
pourrait
augment
le
risqu
de
un
syndrom
respiratoir
aigu
en
ca
dinfect
au
est
une
enzym
carboxypeptidas
qui
contribu
linactiv
de
langiotensin
ii
et
par
soppos
physiologiqu
aux
effet
de
langiotensin
ii
le
iec
ninhib
pa
bien
quil
ait
vitro
que
le
arb
positiv
lexpress
tissulair
de
le
chez
lhomm
ne
sont
pa
concordant
de
plu
ce
jour
il
n
pa
de
pour
soutenir
quun
traitement
par
iec
ou
arb
pourrait
facilit
cellulair
du
sra
en
augment
lexpress
membranair
et
tissulair
enfin
certain
soutienn
selon
laquel
laugment
de
lexpress
membranair
ladministr
darb
ou
ladministr
dace
solubl
circulant
pourrait
de
effet
protecteur
potentiel
sur
la
survenu
de
tissulair
inflammatoir
en
ca
dinfect
par
le
de
essai
sont
en
cour
en
sur
la
base
de
preuv
actuel
dispon
et
comm
le
de
nombreus
savant
le
iec
ou
arb
ne
doivent
pa
interrompu
en
raison
dune
infect
par
le
en
dehor
de
situat
la
situat
est
avec
alor
un
ajust
au
ca
par
ca
mot
clef
hypertens
multipl
sever
acut
respiratori
syndrom
case
due
sar
concern
angiotensinconvert
enzym
inhibitor
acei
angiotensin
ii
type
receptor
blocker
arb
emerg
angiotensinconvert
enzym
enzym
receptor
allow
sar
entri
cell
fear
preexist
treatment
acei
arb
might
increas
risk
develop
sever
fatal
sever
acut
respiratori
syndrom
case
infect
present
articl
discuss
concern
membranebound
enzym
carboxypeptidas
contribut
inactiv
angiotensin
ii
therefor
physiolog
counter
angiotensin
ii
effect
acei
inhibit
although
arb
shown
upregul
tissu
express
experiment
anim
evid
alway
consist
human
studi
moreov
date
evid
acei
arb
administr
facilit
sar
cell
entri
increas
tissu
express
either
anim
human
studi
final
studi
support
hypothesi
elev
membran
express
tissu
activ
administr
arb
andor
infus
solubl
could
confer
protect
properti
inflammatori
tissu
damag
infect
summari
base
current
avail
evid
advoc
mani
medic
societi
acei
arb
discontinu
concern
infect
except
hemodynam
situat
precari
casebycas
adjust
requir
keyword
reninangiotensinaldosteron
system
arteri
hypertens
cardiovascular
patient
show
increas
risk
sever
form
coronaviru
covid
infect
clinic
manifest
princip
respiratori
patient
may
also
show
cardiovascular
complic
present
articl
review
current
state
knowledg
regard
relat
reninangiotensinaldosteron
system
raa
particularli
raa
blocker
human
physiolog
peptid
degrad
limit
number
nonspecif
extracellular
enzym
known
peptidas
proteas
membran
protein
activ
site
face
extracellular
space
endopeptidas
cut
within
peptid
chain
exopeptidas
releas
cor
ntermin
amino
acid
angiotensinconvert
enzym
exopeptidas
carboxypeptidas
rel
specif
amino
acid
surround
cut
site
although
may
common
sever
peptid
therefor
import
awar
given
peptidas
specif
given
peptid
angiotensinconvert
enzym
enzym
carboxypeptidas
mainli
locat
membran
circul
form
creat
enzym
splice
membran
anchor
homolog
angiotensinconvert
enzym
formerli
simpli
known
ace
better
denot
first
describ
downregul
reninangiotensin
system
act
deactiv
angiotensin
ii
also
known
angiotensin
activ
peptid
caus
vasoconstrict
profibrosi
proinflamm
action
stimul
aldosteron
secret
bind
receptor
convert
angiotensin
activ
peptid
opposit
properti
angiotensin
ii
sever
anim
studi
show
angiotensin
bind
ma
receptor
induc
vasodilat
show
antifibrosi
antiinflammatori
properti
figur
angiotensin
ii
also
deactiv
aminopeptidas
convert
angiotensin
ii
angiotensin
iii
induc
vasodilat
increas
natriuresi
bradykinin
preferenti
bind
receptor
greater
affin
receptor
also
convert
angiotensin
also
known
angiotensin
angiotensin
unknown
action
convert
angiotensin
raa
thu
divid
activ
system
compris
classic
histor
angiotensin
pathway
inhibitor
system
compris
angiotensin
pathway
latter
abl
deactiv
angiotensin
ii
counter
effect
pharmacolog
angiotensin
pathway
contrast
angiotensin
pathway
littl
explor
invitro
studi
show
benefici
cardiovascular
impact
activ
possibl
involv
gmpc
elev
also
report
interact
receptor
target
angiotensin
ii
receptor
blocker
arb
arb
counter
effect
angiotensin
ii
thu
stimul
angiotensin
ii
liber
respons
increas
angiotensin
ii
thu
increas
express
seem
express
cell
variou
organ
includ
heart
kidney
vessel
digest
tract
testicl
ent
region
lung
enter
infect
cell
coronaviru
recogn
via
spike
surfac
glycoprotein
bind
membran
receptor
protein
lipid
carbohydr
depend
prior
activ
spike
protein
human
proteas
includ
membran
enzym
extracellular
domain
seem
provid
entri
human
cell
sar
therefor
act
receptor
coronaviru
figur
precis
identif
sar
spike
glycoprotein
bind
site
show
latter
ident
sar
cov
despit
two
virus
distinct
show
homolog
moreov
affin
sar
greater
sar
cov
spike
protein
activ
proteas
follow
sar
bind
extracellular
domain
membran
explain
viru
bind
penetr
cell
see
figur
refer
convers
circul
solubl
bind
sar
unabl
induc
cell
infect
experiment
antibodi
target
sar
cov
seem
also
block
sar
bind
suggest
possibl
therapeut
strategi
notabl
reposit
certain
proteas
inhibitor
certain
invitro
studi
report
posit
correl
membran
express
andor
tissu
activ
risk
infect
moreov
bind
viru
induc
decreas
tissu
activ
thu
aggrav
inflamm
organ
notabl
lung
invitro
studi
report
decreas
membran
express
mous
lung
follow
sar
cov
administr
concomit
respiratori
impair
administr
arb
losartan
improv
respiratori
function
perhap
restor
membran
express
tissu
activ
thu
level
membran
express
andor
tissu
activ
may
influenc
onset
infect
thu
risk
develop
sever
inflammatori
tissu
injuri
likewis
recent
retrospect
studi
chines
patient
requir
hospit
admiss
show
hypokalemia
author
explain
alter
angiotensin
ii
deactiv
shift
balanc
reduc
tissu
activ
favor
thu
induc
aldosteron
synthesi
hypokalemia
occurr
figur
hypothesi
confirm
mineralocorticoid
receptor
blocker
may
abl
contribut
correct
hypokalemia
therefor
clear
particularli
membran
express
tissu
activ
play
key
role
infect
exact
role
howev
complex
may
deleteri
contamin
phase
act
receptor
sever
may
correl
membran
express
tissu
activ
benefici
inflammatori
lesion
phase
mani
question
thu
remain
present
unansw
knowledg
pharmacolog
activ
inhibitor
avail
date
human
group
suggest
use
circul
solubl
captur
mani
virus
possibl
plasma
restrict
fixat
cellmembran
thu
limit
cell
infect
invitro
studi
show
genet
engin
recombin
solubl
could
use
therapeut
option
moreov
solubl
might
favor
angiotensin
pathway
angiotensin
pathway
prevent
treat
sever
inflammatori
tissu
lesion
human
recombin
solubl
fdaapprov
treatment
sinc
phaseii
trial
acut
respiratori
distress
syndrom
would
allow
rapid
transfer
dedic
clinic
trial
launch
soon
angiotensinconvert
enzym
inhibitor
acei
princip
inhibit
thu
block
angiotensin
ii
releas
figur
action
never
report
thought
effect
acei
like
arb
wide
prescrib
mainten
therapi
sever
chronic
cardiovascular
diseas
includ
arteri
hypertens
heart
failur
diabet
nephropathi
invitro
model
free
report
acei
arb
treatment
increas
membran
express
especi
heart
invitro
find
human
studi
healthi
subject
discord
also
born
mind
circul
level
may
match
membran
express
tissu
activ
latter
possibl
vari
depend
tissu
certain
invitro
studi
report
low
level
circul
despit
high
membran
thu
tissu
express
also
evid
impact
aceiarb
pulmonari
express
notabl
context
group
suggest
increas
angiotensin
ii
express
may
underli
compensatori
respons
increas
express
human
arb
could
thu
induc
elev
acei
inhibit
angiotensin
ii
releas
likewis
arb
block
receptor
may
favor
convers
angiotensin
ii
angiotensin
iii
enhanc
benefit
receptor
activ
figur
also
keep
mind
cardiovascular
diseas
notabl
ischem
cardiopathi
heart
failur
arteri
hypertens
diabet
associ
increas
membran
express
tissu
activ
anim
model
independ
aceiarb
administr
clinic
situat
infect
contract
yet
contract
patient
without
cardiovascular
histori
infect
probabl
play
major
role
studi
report
high
level
aceiarb
infect
especi
sever
form
requir
hospit
icu
admiss
although
notic
arteri
hypertens
common
especi
elderli
aceiarb
prescrib
case
thu
posit
neg
impact
aceiarb
human
remain
unknown
complex
possibl
even
depend
clinic
stage
neg
contamin
phase
benefici
tissu
inflamm
phase
studi
question
forthcom
earli
data
extract
retrospect
studi
perform
china
potenti
confound
factor
exhibit
reassur
result
possibl
benefici
effect
mortal
aceisarb
author
suggest
arb
acei
may
provid
benefit
infect
prevent
onset
sever
tissu
lesion
two
clinic
trial
losartan
arb
without
hospit
admiss
due
launch
thu
mani
scientif
societi
includ
french
societi
arteri
hypertens
sfhta
european
societi
cardiolog
see
http
wwwsfhtaeu
mani
public
advis
stop
mainten
treatment
attempt
prevent
infect
especi
imbal
blood
pressur
heart
failur
may
deleteri
remain
difficult
unansw
question
longcours
aceiarb
therapi
case
infect
especi
sever
individu
person
attitud
seem
essenti
consid
clinic
present
sever
hemodynam
respiratori
renal
failur
blood
pressur
etc
indic
acei
arb
noncompl
hypertens
heart
failur
impair
lvef
etc
also
notic
effect
acei
arb
infect
unknown
two
may
guidelin
may
rapidli
revis
light
incom
data
ongo
clinic
trial
especi
concern
arb
antihypertens
cardiovascular
drug
dihydropyridin
combin
sacubitrilvalsartan
thiazid
diuret
mineralocorticoid
receptor
antagonist
affect
invitro
tissu
express
regard
betablock
retriev
singl
invitro
studi
report
impact
atenolol
aortic
tissu
express
found
studi
impact
loop
diuret
tissu
express
although
impact
physiolog
conceiv
present
theoret
concern
around
aceiarb
requir
detail
dedic
human
studi
seem
clear
key
point
sar
cellentri
therefor
repres
reason
pharmacolog
target
reduc
membran
activ
tissu
express
especi
lung
prevent
infect
reduc
sever
patient
yet
experienc
inflammatori
lesion
may
repres
valuabl
option
prevent
onset
sever
inflammatori
tissu
lesion
especi
lung
hand
angiotensin
pathway
favor
angiotensin
pathway
order
increas
membran
express
andor
tissu
activ
pharmacolog
therapeut
target
eg
arb
circul
solubl
also
therapeut
option
actual
evalu
question
current
unresolv
scrupul
investig
ongo
trial
angiotensinconvert
enzym
angiotensinconvert
enzym
arb
angiotensin
ii
receptor
blocker
acei
angiotensinconvert
enzym
inhibitor
